"uuid:ID","versionIdentifier","rationale","id","instanceType"
"8002a703-63f9-41b0-8ec5-a719209c9075","2","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion_1","StudyVersion"
